dantrolene has been researched along with Cerebral Palsy in 22 studies
Dantrolene: Skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in the muscle fiber. It is used in spasticity and other neuromuscular abnormalities. Although the mechanism of action is probably not central, dantrolene is usually grouped with the central muscle relaxants.
dantrolene : The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia.
Cerebral Palsy: A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double-blind study was carried out on 20 children with spasticity secondary to cerebral palsy, in order to compare the effects of dantrolene sodium suspension and a placebo." | 9.05 | Dantrolene sodium suspension in treatment of spastic cerebral palsy. ( Joynt, RL; Leonard, JA, 1980) |
| "In this two-phase study, 21 pediatric patients with epilepsy and spasticity were initially treated with dantrolene sodium suspension and, after a washout period, began a double-blind portion where one half received dantrolene sodium suspension and the other half received a placebo suspension." | 9.04 | Effect of dantrolene sodium on the incidence of seizures in children with spasticity. ( Nogen, AG, 1979) |
| "We report a case of a 49-year-old female with cerebral palsy with spastic tri-plegia and lumbar spondyolisthesis diagnosed to have overactive neurogenic bladder, which improved on treatment with Dantrolene along with antimuscarinics." | 7.81 | Dantrolene an unusual option for detrusor overactivity: observations of a patient with cerebral palsy. ( Bulchandani, S; Kennedy, A; Sturman, S; Toozs-Hobson, P, 2015) |
| "Serum concentration of dantrolene and its active metabolite, 5-hydroxydantrolene were determined in 27 cerebral palsy patients." | 7.67 | Relationship between serum concentration and daily dose of dantrolene in cerebral palsy patients. ( Chikazawa, S; Higashi, A; Inotsume, N; Matsuda, I; Matsukane, I; Nakano, M, 1986) |
| "A double-blind study was carried out on 20 children with spasticity secondary to cerebral palsy, in order to compare the effects of dantrolene sodium suspension and a placebo." | 5.05 | Dantrolene sodium suspension in treatment of spastic cerebral palsy. ( Joynt, RL; Leonard, JA, 1980) |
| "In this two-phase study, 21 pediatric patients with epilepsy and spasticity were initially treated with dantrolene sodium suspension and, after a washout period, began a double-blind portion where one half received dantrolene sodium suspension and the other half received a placebo suspension." | 5.04 | Effect of dantrolene sodium on the incidence of seizures in children with spasticity. ( Nogen, AG, 1979) |
| "We report a case of a 49-year-old female with cerebral palsy with spastic tri-plegia and lumbar spondyolisthesis diagnosed to have overactive neurogenic bladder, which improved on treatment with Dantrolene along with antimuscarinics." | 3.81 | Dantrolene an unusual option for detrusor overactivity: observations of a patient with cerebral palsy. ( Bulchandani, S; Kennedy, A; Sturman, S; Toozs-Hobson, P, 2015) |
| "The author's clinical experience with the use of dantrolene in children with cerebral palsy is discussed." | 3.67 | Long-term treatment of spasticity in children with cerebral palsy. ( Molnar, GE, 1987) |
| "Serum concentration of dantrolene and its active metabolite, 5-hydroxydantrolene were determined in 27 cerebral palsy patients." | 3.67 | Relationship between serum concentration and daily dose of dantrolene in cerebral palsy patients. ( Chikazawa, S; Higashi, A; Inotsume, N; Matsuda, I; Matsukane, I; Nakano, M, 1986) |
| "Forty patients, whose ages varied from 4 to 65 years, presenting skeletal muscle spascitiy as sequel of cerebral palsy, spinovertebral trauma and cerebral vascular diseases were treated with Dantrium (dantrolene sodium), a drug muscle relaxing." | 3.65 | [Sodium dantrolene (dantrium) in the treatment of neurogenic muscular spasm]. ( Alvarenga, H; Araújo Leitão, RE; Couto, B; Figuereido, HB; Gomes Marleide, M; Melo Reis, CH, 1976) |
| "The results indicate that the spasticity of cerebral palsy can be relieved significantly, and that the combination of peripherally and centrally acting agents is more beneficial than either medication alone." | 2.64 | Medical treatment for spasticity in children with cerebral palsy. ( Nogen, AG, 1976) |
| "While in some children, spasticity may adversely impact the motor abilities, in others, it may help maintain posture and ability to ambulate." | 2.43 | Pharmacologic interventions for reducing spasticity in cerebral palsy. ( Patel, DR; Soyode, O, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (54.55) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 2 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bulchandani, S | 1 |
| Toozs-Hobson, P | 1 |
| Kennedy, A | 1 |
| Sturman, S | 1 |
| Kasatkin, DS | 1 |
| Chung, CY | 1 |
| Chen, CL | 1 |
| Wong, AM | 1 |
| Patel, DR | 1 |
| Soyode, O | 1 |
| Tsuchiya, N | 1 |
| Morimura, E | 1 |
| Hanafusa, T | 1 |
| Shinomura, T | 1 |
| Dowling, CR | 1 |
| Reddihough, D | 1 |
| Smith, P | 1 |
| Webb, N | 1 |
| McNeill, R | 1 |
| Clouston, D | 1 |
| Joynt, RL | 1 |
| Leonard, JA | 1 |
| Boshoff, L | 1 |
| Bodensteiner, JB | 1 |
| Krach, LE | 1 |
| Pinder, RM | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Nogen, AG | 2 |
| Vining, EP | 1 |
| Accardo, PJ | 1 |
| Rubenstein, JE | 1 |
| Farrell, SE | 1 |
| Roizen, NJ | 1 |
| Couto, B | 1 |
| Figuereido, HB | 1 |
| Araújo Leitão, RE | 1 |
| Alvarenga, H | 1 |
| Gomes Marleide, M | 1 |
| Melo Reis, CH | 1 |
| Denhoff, E | 1 |
| Feldman, S | 1 |
| Smith, MG | 1 |
| Litchman, H | 1 |
| Holden, W | 1 |
| Molnar, GE | 1 |
| Pace-Balzan, A | 1 |
| Ramsden, RT | 1 |
| Inotsume, N | 1 |
| Higashi, A | 1 |
| Matsukane, I | 1 |
| Chikazawa, S | 1 |
| Nakano, M | 1 |
| Matsuda, I | 1 |
| Chyatte, SB | 2 |
| Basmajian, JV | 1 |
| Birdsong, JH | 1 |
| Roberson, DL | 1 |
5 reviews available for dantrolene and Cerebral Palsy
| Article | Year |
|---|---|
Pharmacotherapy of spasticity in children with cerebral palsy.
Topics: Baclofen; Benzodiazepines; Cerebral Palsy; Child; Clonidine; Dantrolene; Humans; Muscle Spasticity; | 2011 |
Pharmacologic interventions for reducing spasticity in cerebral palsy.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Age Factors; Anti-Infective Agents, Local; Baclofen | 2005 |
Pharmacotherapy of spasticity: oral medications and intrathecal baclofen.
Topics: Acetates; Administration, Oral; Amines; Anti-Anxiety Agents; Baclofen; Benzodiazepines; Cerebral Pal | 2001 |
Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity.
Topics: Adult; Animals; Cats; Cerebral Palsy; Chemical and Drug Induced Liver Injury; Child; Clinical Trials | 1977 |
Cerebral palsy. A pediatric developmentalist's overview.
Topics: Cerebral Palsy; Dantrolene; Diazepam; Humans; Levodopa; Occupational Therapy; Phenothiazines; Physic | 1976 |
7 trials available for dantrolene and Cerebral Palsy
| Article | Year |
|---|---|
Dantrolene sodium suspension in treatment of spastic cerebral palsy.
Topics: Activities of Daily Living; Administration, Oral; Adolescent; Cerebral Palsy; Child; Child, Preschoo | 1980 |
Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity.
Topics: Adult; Animals; Cats; Cerebral Palsy; Chemical and Drug Induced Liver Injury; Child; Clinical Trials | 1977 |
Effect of dantrolene sodium on the incidence of seizures in children with spasticity.
Topics: Adolescent; Anticonvulsants; Cerebral Palsy; Child; Child, Preschool; Clinical Trials as Topic; Dant | 1979 |
Medical treatment for spasticity in children with cerebral palsy.
Topics: Cerebral Palsy; Child; Child, Preschool; Clinical Trials as Topic; Dantrolene; Diazepam; Female; Hum | 1976 |
Treatment of spastic cerebral-palsied children with sodium dantrolene.
Topics: Cerebral Palsy; Child; Child, Preschool; Clinical Trials as Topic; Dantrolene; Female; Humans; Hydan | 1975 |
Dantrolene sodium: long-term effects in severe spasticity.
Topics: Activities of Daily Living; Adolescent; Adult; Alkaline Phosphatase; Aspartate Aminotransferases; Ce | 1973 |
Dantrolene sodium in athetoid cerebral palsy.
Topics: Activities of Daily Living; Administration, Oral; Adolescent; Adult; Athetosis; Cerebral Palsy; Chil | 1973 |
11 other studies available for dantrolene and Cerebral Palsy
| Article | Year |
|---|---|
Dantrolene an unusual option for detrusor overactivity: observations of a patient with cerebral palsy.
Topics: Cerebral Palsy; Dantrolene; Female; Humans; Middle Aged; Muscle Relaxants, Central; Urinary Bladder, | 2015 |
[Pathogenetic therapy of spasticity].
Topics: Adult; Aged; Animals; Cerebral Palsy; Child; Controlled Clinical Trials as Topic; Dantrolene; Diseas | 2008 |
Dantrolene: new indication. Cerebral palsy in children: uncertain clinical benefit.
Topics: Cerebral Palsy; Child; Dantrolene; Drug Approval; France; Humans; Muscle Relaxants, Central; Muscle | 2008 |
Postoperative neuroleptic malignant syndrome that occurred repeatedly in a patient with cerebral palsy.
Topics: Anesthesia, General; Antipsychotic Agents; Body Temperature; Cerebral Palsy; Child; Creatine Kinase; | 2007 |
Transitional cell carcinoma in the paediatric population: be aware of unusual aetiologies.
Topics: Carcinoma, Transitional Cell; Cerebral Palsy; Child; Comorbidity; Dantrolene; Female; Hematuria; Hum | 2007 |
Malignant hyperthermia--still around.
Topics: Cerebral Palsy; Dantrolene; Hernia, Inguinal; Humans; Infant; Malignant Hyperthermia | 1995 |
The management of cerebral palsy: subjectivity and a conundrum.
Topics: Baclofen; Botulinum Toxins; Cerebral Palsy; Dantrolene; Humans; Muscle Relaxants, Central; Muscle Sp | 1996 |
[Sodium dantrolene (dantrium) in the treatment of neurogenic muscular spasm].
Topics: Adolescent; Adult; Aged; Cerebral Palsy; Cerebrovascular Disorders; Child; Child, Preschool; Dantrol | 1976 |
Long-term treatment of spasticity in children with cerebral palsy.
Topics: Cerebral Palsy; Child; Dantrolene; Gait; Humans; Long-Term Care; Muscle Spasticity | 1987 |
Sudden bilateral sensorineural hearing loss during treatment with dantrolene sodium (dantrium).
Topics: Adult; Cerebral Palsy; Dantrolene; Female; Hearing Loss, Sudden; Humans | 1988 |
Relationship between serum concentration and daily dose of dantrolene in cerebral palsy patients.
Topics: Adolescent; Adult; Cerebral Palsy; Child; Child, Preschool; Dantrolene; Dose-Response Relationship, | 1986 |